Related Experiment Video
Updated: Jun 12, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Niacin's role in the statin era
Erica L Brooks1, Jeffrey T Kuvin, Richard H Karas
1Preventive Cardiology Center, Tufts Medical Center, Division of Cardiology, Department of Medicine, 800 Washington Street, Box 80, Boston, MA 02111, USA. rkaras@tuftsmedicalcenter.org
Expert Opinion on Pharmacotherapy
|June 24, 2010
Summary
Combining niacin with statin therapy offers favorable lipid changes and appears safe. This combination may significantly reduce cardiovascular event risk, though large trials are needed for confirmation.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Lipidology
Background:
- Statin therapy is widely used to reduce cardiovascular events, but further risk reduction is needed.
- High-density lipoprotein cholesterol (HDL-C) is a key target for cardiovascular disease prevention.
- Niacin is the most effective available agent for increasing HDL-C levels.
Purpose of the Study:
- To review the efficacy and safety of combining niacin with statin therapy.
- To evaluate the impact of this combination on cardiovascular endpoints and clinical outcomes.
Main Methods:
- Systematic review of studies published from 2001 to present.
- Studies identified via MEDLINE and reference list searches.
- Focus on trials combining statin and niacin therapy.
Main Results:
- Concurrent niacin and statin therapy demonstrates multiple beneficial effects on lipid profiles.
- The combination therapy appears to have a safety profile comparable to individual drug use.
- Evidence suggests potential for substantial reductions in adverse cardiovascular events.
Conclusions:
- Adding niacin to statin therapy favorably alters lipid levels and shows comparable safety.
- This combination therapy holds promise for significantly reducing cardiovascular event risk.
- Further large-scale clinical outcome trials are essential to validate these potential benefits.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:29Cholesterol: Significance and Regulation
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...